The profile of hypertension and dyslipidemia in prediabetic subjects; results of the Isfahan Diabetes Prevention program: A large population-based study

Authors
Bijan Iraj 1
Ramin Salami 1
Awat Feizi 2
Massoud Amini 1
1 Department of Clinical Nutrition, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: The present study was designed to evaluate hypertension and dyslipidemia in prediabetic subjects with a family history of type 2 diabetes (first-degree relatives), and they were compared with the normal glucose-tolerance subjects.
Materials and Methods: Three thousand and eighty-six (788 men and 2298 women) subjects were selected from a consecutive sample of patients with Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG), and Combined (IFG and IGT), and their first-degree relatives formed the control group. Potential risk factors for diabetes including age, gender, body size, HbA1c, cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, blood pressure (BP), urine microalbumin, and family and personal medical history were assessed.
Results: The studied participants included 300 IGT patients (9.7%), 625 IFG patients (44.9%), 411 combined patients (13.3%), and 1750 (56.7%) normal subjects. Aging led to increase in hypertension. Increase in body mass index (BMI) led to an increase in the prevalence of hypertension significantly in all groups. The mean triglyceride in the normal group was different in comparison with that of the IGT (P < 0.05) and combined (P < 0.001) groups. Differences in total cholesterol were observed in the normal group when compared with the IGT (P < 0.05) and combined (P < 0.001) groups, and of the combined group in comparison with the IGT (P < 0.05) group. The difference in LDL level was related to the combined group in comparison with IGT, marginally (P < 0.1), and normal in comparison with the combined group (P < 0.05).
Conclusion: Prevalence of hypertension was not significantly different between the groups, however, in prediabetic patients it was higher than in the normal group, and prevalence of dyslipidemia in prediabetic subjects was significantly higher than in the normal group.

Keywords

1.
Deedwania PC, Fonseca VA. Diabetes, prediabetes and cardiovascular risk: Shifting the paradigm. Am J Med 2005;11:939-47.  Back to cited text no. 1
    
2.
Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: A systematic review of the evidence. J Am Coll Cardiol 2010;55:1310-7.  Back to cited text no. 2
    
3.
Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012;59:635-43.  Back to cited text no. 3
    
4.
American Diabetes Association. Position statement: Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30 Suppl 1:S42-7.  Back to cited text no. 4
    
5.
Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008;14:933-46.  Back to cited text no. 5
    
6.
Alberti KG. Screening and diagnosis of prediabetes: Where are we headed? Diabetes Obes Metab 2007;9 Suppl 1:12-6.  Back to cited text no. 6
    
7.
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet 2006;368:1096-105.  Back to cited text no. 7
    
8.
Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147-55.  Back to cited text no. 8
    
9.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28 Suppl 1:S4-36.  Back to cited text no. 9
    
10.
Ferrannini E, Gastaldelli A, Iozzo P. Pathophysiology of prediabetes. Med Clin North Am 2011;95:327-39, vii-viii.  Back to cited text no. 10
    
11.
Liu J, Grundy SM, Wang W, Smith SC Jr, Vega GL, Wu Z, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007;153:552-8.  Back to cited text no. 11
    
12.
Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17 Suppl 2:1-53.  Back to cited text no. 12
    
13.
Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall study. Diabetes Care 2006;29:26-31.  Back to cited text no. 13
    
14.
Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al.;Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880-90.  Back to cited text no. 14
    
15.
Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005;2:9-15.  Back to cited text no. 15
    
16.
Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: The Australian diabetes obesity, and lifestyle study (AusDiab). Circulation 2007;116:151-7.  Back to cited text no. 16
    
17.
American Diabetes Association. Standards of Medical Care in Diabetes--2010. Diabetes Care 2010;33 Suppl 1:S11-61.  Back to cited text no. 17
    
18.
Chen LK, Lin MH, Chen ZJ, Hwang SJ, Tsai ST, Chiou ST. Metabolic characteristics and insulin resistance of impaired fasting glucose among the middle-aged and elderly Taiwanese. Diabetes Res Clin Pract 2006;71:170-6.  Back to cited text no. 18
    
19.
Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors; Results from the Baltimore Longitudinal Study on Aging. Diabetes 2004;53:2095-100.  Back to cited text no. 19
    
20.
Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, et al. Impaired fasting glucose or impaired glucose tolerance: What best predicts future diabetes in Mauritius? Diabetes Care 1999;22:399-402.  Back to cited text no. 20
    
21.
Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.  Back to cited text no. 21
    
22.
Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000;23:1108-12.  Back to cited text no. 22
Advanced Biomedical Research
Volume 2015, January
January 2015
Pages 1-6